David joined Frazier Healthcare Partners in 2014 as a Venture Partner and is focused on new company creation. In this capacity, he co-founded Outpost Medicine, Phathom Pharmaceuticals, and Scout Bio. He was also involved in the formation of Arcutis, and helped launch Passage Bio. David was CEO of Scout and currently serves as CFO of Phathom.
Prior to joining Frazier, David co-founded Incline Therapeutics in 2010 and served as its President and Chief Operating Officer until its sale to The Medicines Company in 2013 for up to $390 million. He also co-founded Cadence Pharmaceuticals in 2004 and served as its Senior Vice President, Corporate Development and Strategy. Cadence completed its IPO in 2006, received FDA approval for OFIRMEV (acetaminophen injection) in 2010, and was acquired by Mallinckrodt in 2013 for $1.3 billion. Both Incline and Cadence are exited portfolio companies of Frazier.
From 2000-2004, David was a Venture Partner at Windamere Venture Partners, where he co-founded companies such as Avera Pharmaceuticals, Kanisa Pharmaceuticals, Somaxon Pharmaceuticals (acquired by Pernix Therapeutics), and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). Previously, he worked at Neurocrine Biosciences, EFO Holdings, and Kaiser Associates.
David holds a B.S. from Georgetown University and an M.B.A. from Stanford University.
How old is David A. Socks?
Mr. Socks is currently 49 years old. There are 4 older executives and no younger executives at Phathom Pharmaceuticals. The oldest executive at Phathom Pharmaceuticals is Dr. Azmi Nabulsi M.D., M.P.H., Co-Founder & COO, who is 65 years old. Learn More on David A. Socks' age.
How do I contact David A. Socks?
Has David A. Socks been buying or selling shares of Phathom Pharmaceuticals?
David A. Socks has not been actively trading shares of Phathom Pharmaceuticals within the last three months. Most recently, David A. Socks sold 15,471 shares of the business's stock in a transaction on Thursday, October 7th. The shares were sold at an average price of $32.66, for a transaction totalling $505,282.86. Learn More on David A. Socks' trading history.
Who are Phathom Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Phathom Pharmaceuticals?
During the last year, Phathom Pharmaceuticals insiders bought shares 2 times. They purchased a total of 3,500 shares worth more than $27,540.00. During the last year, insiders at the sold shares 7 times. They sold a total of 3,746,858 shares worth more than $30,400,962.92. The most recent insider tranaction occured on April, 8th when CFO Molly Henderson sold 3,435 shares worth more than $38,128.50. Insiders at Phathom Pharmaceuticals own 7.5% of the company.
Learn More about insider trades at Phathom Pharmaceuticals. Information on this page was last updated on 4/8/2024.
